UnfoldIP

Company patents

Alector LLC

Alector LLC's patent strategy is heavily concentrated in Peptides & Proteins, which accounts for 97.0% of its portfolio, showing significant growth in 2024 with a +92.3% YoY increase, yet a surprising complete halt in new patent filings across all categories so far in 2026. Despite this, the company also demonstrated an emerging focus in Material & Chemical Analysis, experiencing a remarkable +400.0% YoY growth in 2024, indicating a potential diversification beyond its core pharmaceutical preparations.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

66 US filings (since 2023) · 4 categories · 6 themes

Antibody Engineering & Therapeutics

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Peptides & ProteinsPharmaceutical PreparationsTherapeutic Activity (Pharma)Material & Chemical Analysis
Who else files here? →
53since 2023
-4.5%YoY
Advanced Biomarker Detection Assays

Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.

Material & Chemical Analysis
Who else files here? →
50since 2023
0.0%YoY
Immunomodulatory Protein Design

Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.

Peptides & Proteins
Who else files here? →
33since 2023
+7.1%YoY
Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Pharmaceutical Preparations
Who else files here? →
9since 2023
+66.7%YoY
Targeted Drug Formulation Delivery

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Pharmaceutical Preparations
Who else files here? →
1since 2023
new
Advanced Cell & Gene Therapiesfiltered

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Peptides & Proteins
Who else files here? →
1since 2023
n/a

Patents

Showing 1-4 of 4

Advanced Cell & Gene Therapies
Page 1 of 1
US 12004494 B2GRANTED
A01K67/027

Siglec transgenic mice and methods of use thereof

Filed:2021-09-14Pub:2024-06-11
Applicant:Alector LLC

Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.

US 11470827 B2GRANTED
A01K67/027

Transgenic mice expressing human TREM proteins and methods of use thereof

Filed:2018-12-12Pub:2022-10-18
Applicant:Alector LLC

Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from TREM1, TREML1, TREM2, TREML2, and TREML4, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human TREM immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human TREM repertoire.

US 20220000083 A1APPLICATION
A01K67/027

SIGLEC TRANSGENIC MICE AND METHODS OF USE THEREOF

Filed:2021-09-14Pub:2022-01-06
Applicant:Alector LLC

Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.

US 11147249 B2GRANTED
A01K67/027

Siglec transgenic mice and methods of use thereof

Filed:2017-12-08Pub:2021-10-19
Applicant:ALECTOR LLC

Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.

1